- Home
- MDIA vs ERNA Comparison
MDIA vs ERNA Comparison
Compare MDIA & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDIA
- ERNA
- Stock Information
- Founded
- MDIA 2019
- ERNA 2018
- Country
- MDIA United States
- ERNA United States
- Employees
- MDIA N/A
- ERNA N/A
- Industry
- MDIA Broadcasting
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- MDIA Consumer Discretionary
- ERNA Health Care
- Exchange
- MDIA Nasdaq
- ERNA Nasdaq
- Market Cap
- MDIA 61.4M
- ERNA 56.4M
- IPO Year
- MDIA N/A
- ERNA N/A
- Fundamental
- Price
- MDIA $1.08
- ERNA $0.42
- Analyst Decision
- MDIA
- ERNA
- Analyst Count
- MDIA 0
- ERNA 0
- Target Price
- MDIA N/A
- ERNA N/A
- AVG Volume (30 Days)
- MDIA 312.4K
- ERNA 30.7M
- Earning Date
- MDIA 11-14-2024
- ERNA 03-13-2025
- Dividend Yield
- MDIA N/A
- ERNA N/A
- EPS Growth
- MDIA N/A
- ERNA N/A
- EPS
- MDIA N/A
- ERNA N/A
- Revenue
- MDIA $69,296,000.00
- ERNA $598,000.00
- Revenue This Year
- MDIA N/A
- ERNA N/A
- Revenue Next Year
- MDIA N/A
- ERNA N/A
- P/E Ratio
- MDIA N/A
- ERNA N/A
- Revenue Growth
- MDIA 94.96
- ERNA 1072.55
- 52 Week Low
- MDIA $0.40
- ERNA $0.22
- 52 Week High
- MDIA $6.86
- ERNA $2.63
- Technical
- Relative Strength Index (RSI)
- MDIA 42.53
- ERNA 54.72
- Support Level
- MDIA $1.00
- ERNA $0.38
- Resistance Level
- MDIA $1.16
- ERNA $0.96
- Average True Range (ATR)
- MDIA 0.12
- ERNA 0.10
- MACD
- MDIA -0.00
- ERNA 0.03
- Stochastic Oscillator
- MDIA 48.48
- ERNA 24.25
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales and events including sponsorships and ticket sales, licensing, and syndication.
About ERNA Eterna Therapeutics Inc.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.